Company ProfilePremium

Nippon Kayaku Co., Ltd.

Company Profile Analysis

Ticker: 4272.T日本化薬株式会社

ESOMAR 23 Corporate BadgeISO Certifications Badge
Nippon Kayaku Co., Ltd. - Company showcase

Year Founded & Workforce

1916

5,946 Employees

Nippon Kayaku Co., Ltd. logo

Nippon Kayaku Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Nippon Kayaku Co., Ltd. Overview

Nippon Kayaku is a 110-year-old Japanese specialty-chemicals and pharmaceuticals group. Its technology base comes from explosives, dyes, polymers, catalyst design and oncology chemistry. It operates three balanced business domains. Mobility & Imaging (39% of FY2025 sales) makes airbag inflators, seatbelt-pretensioner micro gas generators (MGGs) and squibs, plus optical films and X-ray components. Fine Chemicals (31%) makes semiconductor-grade epoxy and maleimide resins, MEMS resists, inkjet and functional dyes, and acrylic/methacrylic-acid catalysts. Life Science (30%) covers oncology drugs, antibody biosimilars, generics, contract manufacturing and agrochemicals. The company says it holds the top global share in MGGs and acrylic-acid catalysts and a leading share in semiconductor epoxy resins, and it is a leading domestic oncology supplier. In FY2025 it reported record sales of JPY 241.9 bn, with 56% generated overseas. It is now in the first phase of a ten-year plan, Evolution2035, which targets about JPY 500 bn of sales and ROE of 15% or more by FY2035. A cash-rich balance sheet (equity ratio 70%) funds aggressive buybacks.


What the company does

Nippon Kayaku manufactures and sells performance chemicals, automotive pyrotechnic safety components, optical and X-ray components, prescription pharmaceuticals (mainly oncology) and agrochemicals. Per the FY2025 Yuho, it reports three segments ("business domains") made up of eight business units:

Mobility & Imaging (M&I): Safety Systems (airbag inflators, seatbelt-pretensioner MGGs, squibs) and Polatechno (LCD components, LCD-projector components, X-ray analysis equipment components).

Fine Chemicals (FC): Functional Materials (epoxy and maleimide resins, curing agents, reactive flame-retardant resins, acrylic esters, UV-curable resins, MEMS resists, LCD and semiconductor cleaners, LCD sealants, semiconductor equipment). Colorant Materials (inkjet dyes, inkjet textile dyes, industrial inkjet inks, image-sensor materials, dichroic dyes, near-infrared absorbers, textile and paper dyes, resin colorants, thermal developers, pigment derivatives). Catalysts (acrylic acid, acrolein and methacrylic acid catalysts).

Life Science (LS): Pharmaceuticals (antineoplastics, biologics, cardiovascular agents, photodynamic diagnostic agents, in-vitro diagnostics, embolic materials, APIs and intermediates, food additives, health-food ingredients, food-quality preservatives, sanitisers). Agro (insecticides, herbicides, fungicides, acaricides, public-health insecticides, soil fungicides, animal repellents). Real Estate (leasing).

Company's own description (paraphrased from the FY2025 Yuho)

The group's corporate vision is "KAYAKU spirit": to keep supplying society with the best products by combining continual progress with conscience. Under the ten-year plan Evolution2035, launched in April 2026, the stated aspiration is to deliver safety, prosperity and inspiration to people and the planet through Kayaku's technologies. The plan aims to create social and economic value together. Management describes combining proprietary "KAYAKU technologies" with business assets accumulated over decades and a culture of taking on challenges. The named technologies are agrochemical synthesis, anticancer and bio, catalyst design, dye synthesis, polymers and explosives. The named business assets are a global supply network, quality assurance, stable supply and technical-service sales.

Business and revenue model

DimensionCharacterisation
Revenue typeAlmost entirely product sales: manufactured goods sold B2B, plus prescription drugs sold through Japanese pharmaceutical wholesalers
Service revenueContract manufacturing (pharma CMO/CDMO, being expanded through the Toyama injectables plant acquired 1 October 2026); minor technical services
LicensingInbound licensing dominates (taletrectinib, necitumumab, darinaparsin, goserelin). Outbound royalty arrangements are mostly intra-group (e.g., inflator/MGG technology licensed to Kayaku (Huzhou) Safety Equipment; colorant technology to Shanghai Kayaku International Trading)
Subscription—
Real estateRental income from Port Plaza Nikka (Fukuyama) and Wako Shopping Plaza (Wako, Saitama). Under JPY 2 bn of annual sales (FY2024 guidance basis: JPY 2.0 bn)
Revenue recognitionOn delivery (domestic) or at the agreed delivery point (exports), net of rebates and returns (Yuho FY2025, accounting policies)

Value-chain position

Safety Systems: Tier-2 automotive supplier. Inflators, MGGs and squibs go to Tier-1 airbag and seatbelt module makers (e.g., Toyoda Gosei, a disclosed strategic shareholding and 2018 alliance partner) and through them to global and Chinese OEMs. Vertically integrated back into gas-generant (propellant) production.

Polatechno: Component maker for projector makers, HUD module makers, X-ray analyser and electron-microscope OEMs.

Functional Materials: Upstream materials supplier to semiconductor encapsulant makers, substrate and laminate makers, MEMS and image-sensor fabs. Also supplies semiconductor back-end equipment (via Teikoku Taping System).

Colorants: Dye supplier to printer OEMs, ink makers, textile printers and thermal-paper makers.

Catalysts: Supplies proprietary oxidation catalysts to acrylic-acid and methacrylic-acid producers.

Pharmaceuticals: Integrated Japanese marketer and manufacturer of oncology drugs (in-licensed innovative drugs, biosimilars, generics), with API/intermediates export and contract manufacturing.

Agro: Discovery, formulation and sale of crop-protection actives (e.g., flometoquin), domestically and overseas.

Customer types and end-markets

End-marketSegmentCustomer type
Automotive passive safetyM&ITier-1 airbag/seatbelt module makers; Chinese domestic OEM programmes are a key growth driver (Yuho FY2025)
Automotive displays (HUD)M&IHUD module makers
Projectors, analytical instrumentsM&IProjector OEMs; X-ray analyser and electron-microscope OEMs
Semiconductors / AI servers / 5G-6G substratesFCEncapsulant, laminate and substrate makers; MEMS and image-sensor fabs
Printing (consumer, industrial, textile), thermal paperFCPrinter OEMs, ink formulators, textile printers, thermal-paper makers
Acrylic monomersFCAcrylic-acid and methacrylic-acid producers
Oncology care (Japan)LSHospitals via wholesalers (Suzuken, Toho, Medipal, Alfresa and Vital KSK are disclosed strategic holdings)
AgricultureLSDistributors and growers (Japan and overseas)

Independent characterisation

Nippon Kayaku is best understood as a portfolio of niche, mid-cap leadership positions linked by shared chemistry rather than by end-market. Its earnings are cyclically diversified. Automotive volumes, semiconductor inventory cycles and Japanese drug-price revisions rarely trough together. The exception was FY2023, when a semiconductor downturn, steep biosimilar price cuts and a large in-licensing payment coincided and operating margin fell to 3.6%. The structural issues are threefold. First, M&I margins are exposed to pass-through lags on raw materials (gold and explosive components are cited). Second, the pharmaceutical franchise relies on generics and biosimilars, which suffer price revisions under Japan's NHI system. Third, capital efficiency has been weak: ROE stayed below 8% for most of FY2021 to FY2024. Evolution2035 Phase 1 is an explicit attempt to rebuild the portfolio toward higher-value products (new oncology drugs, CDMO, advanced semiconductor resins) and inorganic growth.

Strategy

KAYAKU Vision 2025 (FY2022–FY2025) — review

KV25 metric (JPY 100 M)FY2022FY2023FY2024FY2025
Sales plan1,9682,0702,1602,300
Sales actual1,9832,0172,2252,418
Operating income plan184200225265
Operating income actual21573204224

Source: Yuho FY2025 ("Results of the Medium-term Business Plan"). FY2025 achievement was 105.2% of plan for sales and 84.7% for operating income. The ROE target of 8% or more was missed (FY2025 actual 9.0% only because of securities gains; management's November 2025 forecast had been 7.7%). The ROIC target is given as 10% in one company document and 6% in another summary; this inconsistency is noted.

Management attributed the shortfalls to the following causes (Nov 2025 policy deck):

M&I: soaring raw-material costs (gold, explosives) and a shrinking monochrome-LCD polariser market.

FC: a delayed semiconductor cycle and slow ramp-up of some new products.

LS: slow market penetration of new drugs and larger-than-expected biosimilar price cuts.

KV25 cash allocation (four-year framework, about JPY 200 bn+). R&D JPY 61.9 bn; M&A and licences JPY 18.9 bn; startup investments JPY 2.6 bn; capex JPY 91.9 bn; dividends JPY 24.6 bn; buybacks JPY 28.0 bn. It was funded partly by debt and cross-shareholding sales (JPY 17.4 bn sold FY2024–FY2025).

Short-term countermeasures adopted in 2024–2025.

  • Exits: projector polariser discontinuation; accelerated discontinuation of non-core drugs; ROIC-based pruning (product groups needing profit improvement are capped at 2% or less of group sales).

  • Capital policy: total payout of 100% or more until ROE reaches 8%; progressive dividend; cancellation of treasury stock above 0.5% of issued shares.

  • Pricing reforms ("profit over sales").

Evolution2035 — long-term plan (FY2026–FY2035)

Aspiration (paraphrased): deliver safety, prosperity and inspiration to people and the planet through Kayaku technologies.

  • Ten-year targets (July 2026 investor presentation via Quartr): sales of about JPY 500 bn by FY2035, roughly double FY2025, and ROE of 15% or more. The plan emphasises inorganic growth (new businesses, M&A) and, in pharma, a shift toward new drugs and contract manufacturing. Pharma management has said it wants new drugs to reach about 30% of pharma sales within roughly ten years (Shimada, Jiho, Feb 2026).

Three phases: Phase 1 runs FY2026–FY2028; Phases 2 and 3 run to FY2035.

Named growth themes (Nov 2025 policy deck): functional dyes, new pharmaceuticals, drone safety devices, flying-car safety devices, space industry, new semiconductor materials, carbon-neutral catalysts, anion-exchange membranes for hydrogen production (NEDO-adopted project), digital-printing inks and X-ray business.

Evolution2035 Phase 1 (FY2026–FY2028) — medium-term targets (Yuho FY2025)

TargetFY2028
Net salesJPY 300 bn
Operating incomeJPY 36 bn (12% margin)
ROE10% or more (achieve 8% early, then double digits)
After-tax ROIC7% or more

Five company-wide priorities:

  1. Build a resilient business portfolio.

  2. Turn KV25 investments into results (raise utilisation of the new epoxy and industrial inkjet capacity; automation).

  3. Optimise cash allocation.

  4. Evolve the organisation for efficiency and speed.

  5. Invest strategically in human capital.

New "Mirai Biz Center" for businesses beyond the existing framework; active use of open innovation, in-licensing, alliances and M&A.

Pharma structural shift (Jiho, 13 May 2026): grow share of new drugs introduced through FY2025, launch biosimilars and generics on a schedule, and expand contract manufacturing.

Treat these as not publicly verified here.

Strategic initiatives announced in the last 24 months

DateInitiativeType
Nov 2024 – Mar 2026Buybacks of JPY 7 bn then JPY 17 bn; cancellations of 5.5 M, 5.0 M and 11.3 M sharesCapital policy
28 Mar 2025"Management conscious of cost of capital and share price" disclosureGovernance / capital
FY2024–FY2025JPY 17.4 bn of strategic shareholdings sold (9 listed names fully exited in FY2025, incl. MUFG, Shin-Etsu, Meiji HD, Toyota Tsusho)Balance-sheet efficiency
2,025Gas cogeneration at Takasaki; multi-site energy service; solar additionsDecarbonisation
Sep–Nov 2025Ibtrogy approval and launchNew drug
2025–2026Takasaki integrated QA building (JPY 4.2 bn), injectables line and biologics linePharma capacity
30 Mar 2026Acquisition of the Toyama injectables CDMO plantPharma CDMO
Apr 2026Evolution2035 launch; Mirai Biz CenterStrategy
12 May 2026Phase 1 targets; JPY 15 bn buyback (to Mar 2027)Strategy / capital
21 May 2026Zoladex marketing authorisation transfer from AstraZenecaProduct acquisition
Sep 2026Sanko Chemical Industry 100% (squeeze-out)Group simplification
OngoingSquib, MGG and inflator capacity in CN, MX, MY and CZ; epoxy (Asa) and dry-film resist (Fukuyama) plantsCapacity
OngoingNEDO-adopted anion-exchange membrane for water electrolysis; PARASAFE with RainmakerTechnology bets

Management guidance (FY2026, year ending March 2027)

ItemInitial (12 May 2026)Revised (3 Aug 2026)
Net sales (JPY bn)260.6270.9 (+12.0% YoY)
Operating income (JPY bn)25.427.3 (+21.6%)
Ordinary income (JPY bn)25.227.0
Net income attributable (JPY bn)22.322.9
EPS (JPY)—158.66
DPS (JPY)66 (33/33)66 (unchanged)
ROE / ROIC8.2% / 5.6%8.4% / 6.0%

Sources: Yahoo! Finance Japan, Monex and Quartr. First-half sales guidance was raised by JPY 10.3 bn to JPY 133.8 bn.

Products & Services

Pricing models are not publicly disclosed for industrial products; they are B2B contract pricing with raw-material pass-through mechanisms that management is renegotiating. Pharmaceutical prices are set by Japan's NHI price list. Launch years are given only where a source confirms them.

Mobility & Imaging — Safety Systems

ProductDescription / capabilitiesTarget customerStatus / notes
Airbag inflators (cylinder type)Pyrotechnic gas generators that inflate side and curtain airbags. A next-generation cylinder inflator design was completed and entered production and sale in FY2025Airbag module makers / OEMsManufactured in Himeji (JP), Huzhou (CN) and Sendayan (MY). The FY2025 Yuho lists two Huzhou inflator lines (JPY 697 M and JPY 960 M)
Airbag inflators (disc type)Driver and passenger frontal inflators; next-generation disc inflator in developmentModule makers / OEMsDevelopment stage (Yuho FY2025)
Micro gas generators (MGGs)Actuators for seatbelt pretensioners. Company claims the top global share (July 2026 investor presentation via Quartr)Seatbelt makers / OEMsMade in Czech Republic, China, Mexico and Malaysia; Mexico and Malaysia MGG line expansions completing 2026
Squibs (initiators)Electrically fired initiators used in inflators, MGGs and other pyrotechnic devices. Company claims a leading global shareSafety-system makersSquib capacity being added in Czechia (JPY 848 M), Huzhou (JPY 2,185 M, completing Sept 2027), Mexico (JPY 745 M) and Malaysia (JPY 1,104 M)
Gas generantsPropellant formulationsInternal / affiliatesMade at Jablůnka (CZ)
PARASAFE® drone parachuteParachute recovery system for drones; adopted by US company Rainmaker for FAA-approved high-altitude cloud-seeding operationsDrone operatorsCommercial (Aero Business Promotion Dept.)
Steerable parachute recovery systemCollision-avoiding parachute system for "flying cars" (eVTOL)eVTOL developers (NK invested in SkyDrive in 2022)Development
Fire-suppression componentsPyrotechnic-actuated initial fire suppression, e.g., for collection of waste batteriesBattery recyclers / industrialResearch stage (Technology Division)
Non-automotive pyrotechnic devicesPyrotechnics for applications beyond auto safetyVariousDevelopment begun (Yuho FY2025)

Mobility & Imaging — Polatechno

ProductDescriptionTarget customerStatus / notes
Dye-based polarising films (automotive high-durability)Integrated from dichroic dye design and synthesis through film formingIn-vehicle display makersPolariser sales flat in FY2025
Light-shielding plates for head-up displays (HUD)Optical parts that block sunlight-induced heat and glare in HUDsHUD module makersGrowing; adoption rising in EVs (Yuho FY2025)
LCD-projector componentsInorganic and wire-grid polarisers and optical components (Moxtek, Wuxi Polatechno Optical)Projector OEMsDeclining. Projector polarisers are being discontinued as a profit-improvement action (Nov 2025 Evolution2035 policy deck)
X-ray analysis equipment componentsX-ray tubes, windows and detectors (Moxtek; Rayspec silicon drift detectors and signal processors)Portable XRF and electron-microscope OEMsFell in FY2025 on customer inventory adjustment; distinctive products in development
Special retardation filmsDejima Optical Films (Netherlands)Display makersNiche
Monochrome-LCD polarisersLegacy productIndustrial LCD makersMarket shrinking (company cites as a KV25 profit drag)

Fine Chemicals — Functional Materials

ProductDescription / applicationTarget customerNotes
Epoxy resins (semiconductor grade)Insulating resins for encapsulants and substrates. Monex profile states world No. 1 for semiconductor encapsulant epoxyEncapsulant and laminate makersNew Asa epoxy plant (JPY 7.45 bn; JPY 7.31 bn spent), completion pushed from Jan 2026 to Jan 2028
Maleimide resinsHigh-heat, low-dielectric resins for AI/5G-6G substratesSubstrate makersGrowth product
Curing agents for epoxyHardenersFormulators—
Reactive flame-retardant resinsHalogen-free flame retardancyLaminate makers—
Acrylic esters / UV-curable resins (KAYARAD® series)Resins for resists and coatings; produced in WuxiResist and coating makers—
MEMS resists (liquid and dry film), incl. the SU-8 family via Kayaku Advanced MaterialsThick-film photoresists for MEMS and image sensorsMEMS and CMOS sensor fabsDry-film resist plant at Fukuyama (JPY 850 M), completion deferred to Apr 2028
LCD and semiconductor cleanersProcess chemicalsFabs—
LCD sealantsDisplay assemblyPanel makers—
Semiconductor manufacturing equipmentLaminators, removers, mounters, UV irradiators (Teikoku Taping System)Back-end semiconductor assemblersEntered via 2021 investment
Epoxy for carbon-fibre-reinforced plasticsComposite matrix resinsComposite makersDevelopment focus
Next-generation materials in R&DLow-dielectric, low-warpage resins; high-heat materials for power semiconductors; new liquid materials—Yuho FY2025 R&D section

Fine Chemicals — Colorant Materials

ProductDescriptionTarget customerNotes
Inkjet printer dyes (consumer)Dyes for home and office inkjetPrinter OEMsDeclined in FY2025
Inkjet textile-printing dyesDigital textile printingTextile printers—
Industrial inkjet inksHigh-speed, high-quality inks for diverse mediaIndustrial printersCapacity added under KV25; utilisation improvement targeted
Image-sensor materialsColour materials for CMOS sensorsSensor makers—
Dichroic dyes for light-control (smart) glassDyes enabling dimmable glazingSmart-glass makersNew product; sales began in FY2025
Near-infrared absorbersFunctional dyesOptics and security printing—
Textile and paper dyesConventional dyes (Wuxi Advanced Kayaku, Thailand)DyehousesMature
Resin colorantsPolymer colouringPlastics processors—
Thermal developers (colour developers)Non-phenol developers for thermal paperThermal-paper makersGrew in FY2025 as US regulation drove non-phenol substitution
Pigment derivatives (synergists)Dispersion aidsPigment and ink makers—

Fine Chemicals — Catalysts

ProductDescriptionTarget customerNotes
Acrylic-acid production catalystsTwo-stage propylene oxidation catalysts. Company claims the top global shareAcrylic-acid producersShipments weighted to the second half; FY2025 sales up on a strong Q4
Acrolein production catalystsFirst-stage oxidationSame—
Methacrylic-acid production catalystsHigh-yield, long-life catalystsMMA/MAA producers—
Green / carbon-neutral catalystsDecarbonisation and hydrogen-economy catalysts; bio-based materials work startedChemical producersR&D

Life Science — Pharmaceuticals

ProductType / indicationOrigin / partnerStatus
Ibtrogy® Capsules 200 mg (taletrectinib adipate)ROS1 TKI for unresectable advanced or recurrent ROS1-fusion NSCLC; active against resistance mutations such as G2032RIn-licensed from AnHeart (now Nuvation Bio) in Oct 2023: USD 40 M upfront plus milestones and royaltiesApproved 19 Sep 2025; launched 12 Nov 2025 (fourth ROS1 agent in Japan). Eisai holds ex-Japan/US/China rights from Jan 2026
Portrazza® (necitumumab)Anti-EGFR antibody for squamous NSCLCLicensed from Eli Lilly (Mar 2019)Marketed; label-expansion trial ongoing (Yuho FY2025)
Darvias® (darinaparsin)Relapsed/refractory peripheral T-cell lymphomaLicensed from Solasia Pharma (Oct 2021); NK holds 12 M Solasia sharesMarketed
Alaglio® (aminolevulinic acid)Photodynamic diagnostic agentPartnership (licensor not confirmed in sources)Marketed; named among new drugs to penetrate
Zoladex® 3.6 mg Depot / LA 10.8 mg Depot (goserelin)LH-RH agonist for prostate cancer, premenopausal breast cancer, endometriosisMarketing authorisation being taken over from AstraZeneca K.K. (contract 21 May 2026; lump-sum payment at completion)Transition timing not confirmed in sources
Antibody biosimilars: Adalimumab BS, Bevacizumab BS (plus legacy infliximab and trastuzumab biosimilars)BiosimilarsIn-house / partnersAdalimumab and bevacizumab BS gaining share (FY2025)
Oncology generics: Lenalidomide capsules, Abiraterone acetate tabletsGenericsIn-houseLaunched in FY2025
Legacy oncology portfolio (about 20 anticancer agents per the Monex profile; incl. bleomycin heritage)Branded and generic cytotoxicsIn-houseSome non-core products being discontinued
Paclitaxel polymeric micelle (NanoCarrier licence, 2002)Nanoparticle oncology formulationNanoCarrierLicence in force (Yuho material contracts)
LHRH antagonist (Aeterna Zentaris licence, 2006)Hormonal oncologyAeterna ZentarisLicence in force
Bladder-cancer agent (Spectrum licence, 2009; Japan and Asia ex-Korea)Urology oncologySpectrumLicence in force
In-vitro diagnostics, embolic materials, cardiovascular agentsHospital productsVariousDiagnostics declined in FY2025
APIs and intermediates; exports; contract manufacturingB2B pharmaIn-house; Toyama plant from Oct 2026Domestic API, exports and contract manufacturing declined in FY2025; CDMO is a Phase 1 growth pillar
Food additives, health-food ingredients, food-quality preservatives, sanitisersFood-tech (Nippon Kayaku Food Techno)In-house—
Buparlisib (pan-PI3K, Japan rights via the Adlai Nortye relationship)Head & neck cancer candidateAdlai NortyeDiscontinued. Adlai Nortye reported the Phase 3 BURAN trial missed its primary overall-survival endpoint and ended development (30 May 2025)

Life Science — Agro and Real Estate

ProductDescriptionNotes
Flometoquin formulationsInsecticide; main overseas growth productFY2025 overseas sales grew; volume expansion is a priority
NK-518New in-house insecticideBuilding the data package for registration
Formulation-improved products and functional spreadersFormulation technologyOne new registration in FY2025
Biostimulants, low-environmental-impact materialsNew agri inputsResearch and in-licensing
Herbicides, fungicides, acaricides, soil fungicides, public-health insecticides, animal repellentsCore domestic portfolioMade at the Kashima Plant
Real estate: Port Plaza Nikka (Fukuyama); Wako Shopping Plaza (Saitama)LeasingFlat in FY2025

Financial Narrative

All figures are consolidated, JPY M, Japanese GAAP. Sources: Yuho FY2021–FY2025; S&P Global Market Intelligence data via StockAnalysis for some cash-flow and balance-sheet line items. Ratios are computed by the analyst from those figures unless otherwise labelled.

Income statement

EBITDA is operating income plus depreciation and amortisation (Envalith; consistent with D&A in the cash-flow statement). The payout series is from Finboard and the FY2025 Yuho.

Margins

Revenue CAGR: FY2021 to FY2025 (4 years) = 6.96%. FY2020 (JPY 173,381 M) to FY2025 (5 years) = 6.9%.

Balance sheet

FY2025 debt composition: short-term borrowings JPY 800 M plus current portion of long-term loans JPY 10,212 M; long-term loans JPY 24,171 M; straight bonds JPY 14,000 M (Yuho FY2025).

Ratios

Management's own KV25 ROIC (company definition) was 8.3% (FY2022), 2.7% (FY2023), 7.1% (FY2024) and about 7.3% forecast for FY2025 (Nov 2025 policy deck via EDINET DB). These differ from the analyst figures above because the definitions differ. StockAnalysis reports TTM ROIC of 6.04%.

Commentary — trends, inflections and drivers

Growth. Sales have grown in each of the last five years, hitting a fifth consecutive record of JPY 241.9 bn in FY2025. Growth came mostly from M&I volume (Chinese domestic OEM programmes, steady global auto production) and yen weakness. Overseas sales were 56% of the total. FY2023 was the only near-stall (+1.7%), when FC sales fell 10.9% in the semiconductor down-cycle.

Profitability inflection. Gross margin has eroded structurally, from 34.6% in FY2021 to 30.1% in FY2025, a fall of 4.5 points. Three causes stand out: raw-material and energy inflation (including gold and explosive inputs in safety products) that pass-through has only partly offset; a mix shift toward lower-margin Safety Systems; and NHI price cuts on biosimilars. The FY2023 collapse in operating margin (3.6%) was amplified by an R&D spike. R&D within SG&A jumped to JPY 19.4 bn from JPY 12.9 bn, which is consistent with expensing the USD 40 M taletrectinib upfront payment (the attribution is the analyst's inference from timing). Since then operating margin has recovered to about 9.3%, but it remains below the 11% of FY2021–FY2022. Management cites price renegotiation and a "profit over sales" mindset as the main FY2026 levers.

Below-the-line support. FY2025 net income (+40.7%) was flattered by JPY 9.4 bn of gains on sales of cross-shareholdings. Against that, the effective tax rate rose to 26.4% from 20.1%. Excluding the securities gains, recurring profit growth was about 14% (ordinary income +14.4%). FY2024 had included a JPY 2.6 bn impairment of investment securities. This coincides with the failure of buparlisib at Adlai Nortye, an NK shareholding; the link is inferred, not confirmed in sources.

Cash flow and capex cycle. Operating cash flow rose steadily to JPY 28.8 bn, but free cash flow compressed sharply. Capex tripled from JPY 8.7 bn (FY2021) to JPY 29.3 bn (FY2024) and JPY 24.5 bn (FY2025) to fund the Asa epoxy plant, squib, MGG and inflator lines in China, Mexico, Malaysia and Czechia, and Takasaki's injectables, biologics and integrated QA buildings. Inventories climbed to 182 days, and working capital absorbed JPY 7.7 bn in FY2025. As a result, record shareholder returns (JPY 27.1 bn in FY2025) were funded by asset sales (JPY 13.3 bn of securities) and new borrowing (net +JPY 7.1 bn).

Balance sheet. The group has moved from a JPY 37 bn net-cash position (FY2021) to near net-neutral (JPY 5.3 bn net cash). It is deliberately lifting leverage to cut its equity-heavy capital structure, with the equity ratio falling from 78.7% to 70.0%. Debt/EBITDA is still only about 1.3x, so there is ample capacity for the M&A-led growth Phase 1 envisages. Goodwill is negligible (JPY 0.5 bn).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentBusiness unitsPrincipal subsidiaries/affiliates

Mobility & Imaging

Safety Systems; Polatechno

Kayaku Safety Systems Europe a.s. (CZ); Kayaku (Huzhou) Safety Equipment (CN); Kayaku Safety Systems de Mexico; Kayaku Safety Systems Malaysia; Nippon Kayaku America (Troy, MI); Nippon Kayaku Korea; Moxtek (US); Wuxi Polatechno Optical (CN); Dejima Tech / Dejima Optical Films (NL); Polatechno Co. (JP, now a land-holding entity); Rayspec (UK)

Fine Chemicals

Functional Materials; Colorant Materials; Catalysts

Kowa Sangyo; Nikka Fine Techno; Kayaku Chemical (Wuxi); Kayaku Advanced Materials (US); Teikoku Taping System; Wuxi Advanced Kayaku Chemical (80%); Shanghai Kayaku International Trading; Nippon Kayaku (Thailand); Euro Nippon Kayaku (Germany)

Life Science

Pharmaceuticals; Agro; Real Estate

Nippon Kayaku Food Techno; Taiwan Nikka; Wako Toshi Kaihatsu; Cultivecs (37.3%, equity method)

Other (outside segments)

Industrial explosives, organic peroxides, chemicals and safety products

Kayaku Japan (50%), Kayaku Nouryon (25%), Sanko Chemical Industry (45% at FY2025-end; 100% from Oct 2026)

Revenue by Segment

Segment (JPY Mn)FY2022FY2023FY2024FY2025

Mobility & Imaging sales

71,86981,20191,37694,714

Fine Chemicals sales

64,04757,07266,20674,142

Life Science sales

62,46363,51865,00172,994

Consolidated net sales

198,380201,791222,584241,851

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment profit (JPY Mn)

Segment profit (JPY Mn)FY2022FY2023FY2024FY2025

Mobility & Imaging profit

8,2158,02813,31110,654

Fine Chemicals profit

10,2215,1839,89911,929

Life Science profit

10,6682,4106,3549,680

Total segment profit

29,10415,62129,56432,263

Unallocated / corporate (incl. corporate R&D)

-7,599-8,284-9,163-9,809

Consolidated operating income

21,5057,33720,40122,454

Segment Margins & Growth (%) and Revenue by Segment (%)

Metric (%)FY2022FY2023FY2024FY2025

M&I segment margin

11.49.914.611.2

FC segment margin

16.09.115.016.1

LS segment margin

17.13.89.813.3

M&I sales growth YoY

—13.012.53.7

FC sales growth YoY

—-10.916.012.0

LS sales growth YoY

—1.72.312.3

M&I share of sales

36.240.241.139.2

FC share of sales

32.328.329.730.7

LS share of sales

31.531.529.230.2

Segment Assets & Liabilities

Metric (JPY Mn)FY2022FY2023FY2024FY2025

M&I segment assets

110,514124,179130,799144,188

FC segment assets

78,16982,55594,49797,021

LS segment assets

83,67484,76586,720104,101

M&I capex

4,6096,7529,4006,700

FC capex

4,8437,7769,0004,000

LS capex

2,6363,8646,6004,000

M&I depreciation

7,0047,0136,7347,107

FC depreciation

3,5933,6073,8114,978

LS depreciation

2,6162,7542,7952,943

Legacy Segment Details

Legacy segmentSales (JPY Mn)Segment profit (JPY Mn)Margin (%)

Functional Chemicals

77,15211,50114.9

Pharmaceuticals

52,0838,64516.6

Safety Systems

46,1126,30613.7

Others (agro, real estate; derived residual)

9,458——

Business Units

Business unitFY2024 forecast (JPY 100 M)

Safety Systems

715

Polatechno

205

Functional Materials

336

Colorant Materials

258

Catalysts

79

Pharmaceuticals

531

Agro

92

Real Estate

20

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Net sales (JPY Mn)

184,805198,380201,791222,584241,851

Sales growth YoY (%)

6.67.31.710.38.7

Gross profit (JPY Mn)

63,96766,75261,30171,48272,880

SG&A incl. R&D (JPY Mn)

42,91645,24753,96451,08050,426

Operating income (JPY Mn)

21,05021,5057,33720,40122,454

EBITDA (JPY Mn)

35,14935,74521,73934,47838,213

Ordinary income (JPY Mn)

23,15423,02512,56222,26625,478

Pre-tax income (JPY Mn)

23,70020,9727,20522,00733,592

Income taxes (JPY Mn)

6,4555,9293,0264,4288,880

Net income attributable to owners (JPY Mn)

17,18114,9844,11317,50824,641

EPS basic (JPY)

101.7089.3624.80107.17161.18

EPS diluted (JPY)

101.6589.3324.79107.16161.18

Dividend per share (JPY)

4045456066

Payout ratio (%)

39.450.4181.556.040.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

Metric (%)FY2021FY2022FY2023FY2024FY2025

Gross margin

34.633.630.432.130.1

Operating margin

11.410.83.69.29.3

EBITDA margin

19.018.010.815.515.8

Net margin

9.37.62.07.910.2

Liquidity & Coverage Ratios and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (JPY Mn)

315,459322,858363,173373,708398,736

Cash & equivalents, CF basis (JPY Mn)

52,96253,09664,77757,92653,368

Cash + short-term investments (JPY Mn)

53,64554,34766,17759,76254,495

Short-term debt incl. current LTD (JPY Mn)

7,1763,38013,4507,21211,013

Long-term debt incl. bonds (JPY Mn)

9,47416,20018,00034,88438,171

Total debt (JPY Mn)

16,65019,58031,45042,09649,184

Net debt, negative = net cash (JPY Mn)

-36,995-34,767-34,727-17,666-5,311

Net assets (JPY Mn)

246,425255,027270,548268,520280,104

Goodwill + intangibles (JPY Mn)

7,5866,5393,6964,0513,755

Inventories (JPY Mn)

55,83471,10667,00871,54184,309

Working capital (JPY Mn)

130,083146,988143,331151,188155,025

Equity ratio (%)

77.878.774.271.670.0

Book value per share (JPY)

1,459.061,532.351,625.181,673.241,878.87

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (JPY Mn)

23,14120,03923,24225,53028,784

Capex, PP&E purchases (JPY Mn)

8,69612,22115,03629,25924,498

Free cash flow (JPY Mn)

14,4457,8188,206-3,7294,286

Depreciation & amortisation (JPY Mn)

14,09914,24014,40214,07715,759

Dividends paid (JPY Mn)

5,0707,5507,8557,39510,559

Share buybacks (JPY Mn)

3,0003,00027,88216,581

Total cash returned (JPY Mn)

8,07010,5507,85715,27727,140

Investing cash flow (JPY Mn)

-10,641-15,158-19,409-27,313-17,184

Financing cash flow (JPY Mn)

-11,090-7,9503,823-4,756-20,235

Proceeds from sale of investment securities (JPY Mn)

———6,01613,297

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE (%, Yuho)

7.36.01.66.59.0

ROA (%, NI / average total assets)

5.64.71.24.86.4

ROIC (%, NOPAT / (equity + debt − cash))

7.37.01.86.56.0

Current ratio (x)

3.844.763.403.723.38

Debt / equity (x)

0.070.080.120.160.18

Net debt / EBITDA (x, negative = net cash)

-1.05-0.97-1.60-0.51-0.14

Interest coverage (x, OI / interest expense)

257209589148

Asset turnover (x)

0.610.620.590.600.63

DSO (days, trade receivables)

123.5102.1112.2105.6106.7

DIO (days)

168.7197.2174.1172.8182.1

DPO (days)

54.445.049.448.052.3

Cash conversion cycle (days)

237.8254.3236.9230.4236.5

Revenue by Region and Revenue by Region (%)

Region (JPY Mn)FY2024FY2025

Japan

96,447106,360

China

46,43451,633

Other Asia

25,76629,503

United States

28,69124,219

Other regions (incl. Europe, Americas ex-US)

25,24430,136

Total

222,582241,851

Overseas sales ratio (%)

56.756.0

Region growth / mix (%)

Region growth / mix (%)FY2025 YoY growthFY2025 share of sales

Japan

10.344.0

China

11.221.3

Other Asia

14.512.2

United States

-15.610.0

Other

19.412.5

Point in Time Details

Point in timePrice (JPY)Source

25 Sep 2026 (latest retrieved close)

2,129.5

Kabuyoho

4 Aug 2026

1,944.5

Monex

28 Jul 2026

1,944.5

StockAnalysis

FY2025 high / low (Apr 2025 – Mar 2026)

2019 / 1219

Yuho FY2025

FY-end share price, implied (JPY)

FY2021

FY2022

Implied from Yuho P/E × EPS

1,1591,188

FY high

1,3221,289

FY low

9821,037

Performance

Value

—

52-week price change (to 28 Jul 2026)

+43.7% (S&P via StockAnalysis)

—

≈1-year (implied Mar-2025 FY-end ~1,415 → 2,129.5 on 25 Sep 2026)

≈ +50% (approximate; derived)

—

5-year total shareholder return (Mar 2021 = 100 → Mar 2026)

188.2 vs. TOPIX incl. dividends 202.2 (Yuho FY2025): underperformed TOPIX by about 14 points

—

3-year TSR (Mar 2023 → Mar 2026, from Yuho index)

188.2 / 119.9 = +57% vs. TOPIX 202.2 / 107.9 = +87% (derived)

—

Beta (5-year)

0.49—

Valuation Multiples

MultipleNippon KayakuSource / datePeer reference

P/E (forecast)

13.8x

Kabuyoho, 25 Sep 2026

Daicel ≈11.8x (Finboard)

P/E (trailing, FY2025 EPS 161.18)

≈13.2x at JPY 2,129.5

Derived

—

P/B

1.11x

Kabuyoho, 25 Sep 2026

—

EV/EBITDA

7.0x (28 Jul 2026, StockAnalysis); 8.3x (Envalith, Jul 2026)

Sources differ on EV

—

EV/Sales

1.11x

StockAnalysis, 28 Jul 2026

—

Dividend yield (forecast)

3.10%

Kabuyoho, 25 Sep 2026

—

DOE

3.6%

EDINET DB

—

Capital Markets

ItemValue

Consensus target price

JPY 2,800 (Kabuyoho, 25 Sep 2026); was JPY 2,550 on 29 Jul 2026

Implied upside

≈31% vs. JPY 2,129.5

Consensus FY2026 ordinary income

JPY 29.5 bn (+15.8%) vs. company JPY 27.0 bn (Sep 2026); was JPY 26.85 bn in Jul 2026

Dividend (JPY per share)

Dividend (JPY per share)FY2021FY2022FY2023FY2024FY2025

Interim

15.020.022.522.530.0

Year-end

25.025.022.537.536.0

Annual

40.045.045.060.066.0

Authorised Details

AuthorisedPeriodLimitExecutedCancellation

13 May 2024

2024—

2,374,800 shares

—

11 Nov 2024

18 Nov 2024 – 30 May 2025

6.5 M shares / JPY 7.0 bn

4,015,800 shares / ≈JPY 5.25 bn (ended 10 Apr 2025)

5.5 M shares (25 Nov 2024); 5,003,570 shares (23 May 2025)

28 Mar 2025

14 Apr 2025 – 31 Mar 2026

14.0 M shares / JPY 17.0 bn

11,224,800 shares / JPY 16.2 bn (ended 26 Mar 2026)

11.3 M shares (22 May 2026)

12 May 2026

13 May 2026 – 31 Mar 2027

13.0 M shares / JPY 15.0 bn

—

Policy: cancel holdings above 0.5% of issued shares

Credit Ratings

AgencyRating / outlook

Moody's

Not rated / not located

S&P

Not rated / not located

Fitch

Not rated / not located

R&I / JCR (domestic)

Not located in this research

Capital Instruments

Instrument (JPY Mn)≤1 yr1–2 yrs2–3 yrs3–4 yrs4–5 yrs>5 yrs

Long-term loans

10,21210,2127,4125,0121,51221

Short-term loans

80000000

Lease obligations

106102715644306

Analyst Conclusions

Guidance and consensus

FY2026 guidance (revised 3 August 2026) calls for sales of JPY 270.9 bn (+12.0%), operating income of JPY 27.3 bn (+21.6%, margin about 10.1%), ordinary income of JPY 27.0 bn and net income of JPY 22.9 bn. Net income is lower than FY2025 because smaller securities gains are expected. The dividend is JPY 66, ROE 8.4% and ROIC 6.0%. The September 2026 sell-side consensus (ordinary income JPY 29.5 bn) sits about 9% above company guidance, which implies the market expects a further upward revision at the 1H results in November 2026. The Phase 1 trajectory requires operating income to compound about 17% a year from JPY 22.5 bn (FY2025) to JPY 36 bn (FY2028), with margin expanding from 9.3% to 12%.

Bull case

  1. Earnings inflection is under way. Q1 FY2026 delivered record sales (+23.1%) and ordinary income +81.7%, prompting a JPY 10.3 bn sales upgrade in the first quarter of the plan. Pharma Q1 sales were up about 28% (Jiho), suggesting Ibtrogy, new generics and biosimilars are scaling.

  2. Capital discipline is real. The company has cancelled about 21.8 M shares (≈13% of the March 2024 issued count) since November 2024. Total payout was 106% in FY2025. A further JPY 15 bn buyback runs to March 2027 (about 5% of market cap). Cross-shareholdings are being liquidated, a classic Japanese governance rerating catalyst at P/B of about 1.1x.

  3. Structural growth exposure at a value multiple. AI-server resins (FC margin 16.1%), Chinese safety content and Japanese oncology CDMO are bought at about 13.8x forward P/E and about 7–8x EV/EBITDA. A balance sheet with debt/EBITDA of about 1.3x leaves room for accretive M&A toward the JPY 500 bn ambition.

Bear case

  1. Margins have not structurally recovered. Gross margin fell 4.5 points in four years, and M&I profit dropped 20% in FY2025 on raw materials. The KV25 operating-income target was missed by 15%, and FY2028's JPY 36 bn target implies execution well beyond the past record (JPY 21.5 bn).

  2. Cash generation is thin. Free cash flow was −JPY 3.7 bn and JPY 4.3 bn in the last two years. FY2025 net income relied on JPY 9.4 bn of securities gains. Shareholder returns have been financed by asset sales and debt (net cash fell from JPY 37 bn to JPY 5 bn). That pace cannot continue indefinitely without stronger FCF.

  3. Pharma and geopolitical tail risks. Annual NHI cuts and a difficult biosimilar market, pipeline concentration on in-licensed assets (buparlisib already failed) and 21% China sales exposure amid US tariffs could derail the plan. The five-year TSR (188) still lags TOPIX (202).

Key catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Early-to-mid Nov 20261H FY2026 results: guidance versus consensus (JPY 29.5 bn ordinary); M&I raw-material pass-through; interim DPS JPY 33
13 Oct 2026 onwardSanko Chemical 100% ownership; Toyama plant integration and capex plans
Late 2026Takasaki integrated QA building (Oct 2026), biologics and injectables lines (Dec 2026) coming online
FY2026Zoladex transition completion; Ibtrogy uptake; Portrazza label-expansion data
FY2026Execution of the JPY 15 bn buyback (through Mar 2027); any further cross-shareholding sales
Feb 2027Q3 FY2026 results; FY2027 dividend signalling
Apr 2027NHI price revision impact on the oncology and biosimilar portfolio
May 2027FY2026 results and first Phase 1 progress review; potential M&A announcements
OngoingUS tariff policy; Japan–China relations; JPY/USD and JPY/CNY rates; semiconductor cycle; gold prices

Analyst verdict

Nippon Kayaku enters Evolution2035 with better operating momentum and clearer capital-allocation discipline than at any point in the past five years. The FY2023 collapse was triple-driven, by the semiconductor cycle, biosimilar price cuts and a front-loaded in-licensing charge, and it has fully reversed. Fine Chemicals now earns a record 16% margin on AI-server resin demand. Life Science profit rose 52% in FY2025 as Ibtrogy and new generics launched, and the group opened FY2026 with record first-quarter sales and an early upgrade. Management has matched this with tangible shareholder actions: about 13% of shares cancelled in roughly 18 months, systematic exit from cross-shareholdings and a total payout above 100%.

The investment case nevertheless hinges on margin repair rather than top-line growth. Sales have compounded at about 7% a year, yet operating margin is still two points below FY2021, and Mobility & Imaging remains a pass-through hostage to gold and explosive input costs. Free cash flow has been negligible through a heavy capex cycle. As a result, returns have been funded by monetising the balance sheet, a finite resource now that net cash is close to zero. The FY2028 targets of JPY 36 bn operating income and a 12% margin are ambitious against a history in which no year exceeded JPY 21.5 bn. Delivery depends on the delayed Asa epoxy plant, the ramp-up of the Takasaki and Toyama pharma capacity, and price discipline in safety products.

At about 13.8x forward earnings, 1.1x book and a 3.1% yield, the shares price in partial delivery. The rerating path is credible if 1H FY2026 confirms margin progress and FCF turns decisively positive as capex normalises. Overall assessment: constructive, with medium conviction. The quality of FY2026 operating-margin expansion and the FCF trajectory are the decisive monitorables, ahead of headline sales growth or further buybacks.


Source notes and data caveats

  1. The company's results presentations and Evolution2035 Phase 1 deck (eir-parts.net) block automated retrieval. Phase 1 segment targets, the cash-allocation quantum, FY2025 business-unit actuals and the Q1 FY2026 segment detail are therefore not reproduced and should be verified against the original IR materials.

  2. Q1 FY2026 consolidated operating income is reported by an aggregator as JPY 8.9 bn.

  3. FY2023 geographic split: Yuho-derived data (overseas 38.2%) conflicts with management's stated 53.6%. A classification change is the likely cause.

  4. Founder attribution differs between data vendors and a Japanese corporate-history source.

  5. Board composition reflects the 19 June 2026 Yuho.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitle / responsibilityBorn (age)Joined / board sincePrior rolesShares held (k)

Shigeyuki Kawamura

Representative Director, President & CEO; chairs the Board and the Nomination & Compensation Advisory Committee

30 Jun 1963 (63)

Joined 1987; Director 2023; President Jun 2025

Himeji Plant procurement head; GM, Kayaku (Huzhou) Safety Equipment (2016); Safety Systems planning head; Head of Safety Systems (2021); Director in charge of M&I and Safety Systems (2023)

33

Hiroshi Shimada

Representative Director, Senior Managing Executive Officer; heads Life Science and Pharmaceuticals

4 Jun 1965 (61)

Joined 1989; Director 2024; Representative Director Jun 2025

President, Nippon Kayaku Food Techno (2018); Pharma API/International/Diagnostics head; Pharma planning

30

Shinji Inoue

Director, Managing Executive Officer; Corporate Planning, Corporate Communications, Accounting, IT; Chair, Crisis Management Committee

6 Feb 1966 (60)

Joined 1988; Director 2024

GM, Shanghai Kayaku Trading (2011); Head of Colorants (2018); Head of Functional Materials (2023); Head of Fine Chemicals (2024)

43

Makoto Takeda

Director, Managing Executive Officer; HR, Legal, General Affairs, Secretariat, Internal Control; Chair, Ethics Committee; export-control officer

17 Jul 1964 (62)

Joined 1988; Director 2024

Secretariat head; HR head

19

Yasuhito Kato

Director, Managing Executive Officer; head of the Technology Division (R&D, RC/technology, sustainability metrics)

3 Mar 1965 (61)

Joined 1990; Director 2025

Head of Agro Research (2016); Head of Agro (2019)

22

Yasuyuki Fujishima

Outside Director (independent)

25 Mar 1947 (79)

Board 2016

MITI; Ambassador to Panama; Executive Vice President, Sojitz; President, Gojokai Hosho

16

Seiichi Fusamura

Outside Director (independent)

18 Mar 1947 (79)

Board 2020

Judge; Director-General, Civil Affairs Bureau, MOJ; Chief Judge of the Sendai and Nagoya High Courts; attorney

0

Ikuko Akamatsu

Outside Director (independent)

27 Feb 1968 (58)

Board 2023

CPA and certified fraud examiner (ex-EY ShinNihon); board roles at SBI Shinsei Bank, Toyo Seikan, MUFG Securities and Brother Industries

0

Mitsuhiro Tsubakimoto

Outside Director (independent)

15 Oct 1959 (66)

Board 2025

Toyota Tsusho senior executive (Asia-Pacific CEO; Chemicals & Electronics); President, Quaker Chemical Japan

0

Directors' Remuneration

CategoryTotal (JPY Mn)FixedPerformance-linked bonusRestricted stockPersons

Inside directors

366197126427

Inside auditors

4747003

Outside officers

7575008

Shigeyuki Kawamura (President)

111

5541141

Board & Management Changes

DateChangeContext

28 Mar 2025 (effective 26 Jun 2025)

Atsuhiro Wakumoto (President since Jun 2019, aged 68) became Senior Advisor; Shigeyuki Kawamura (61, Safety Systems career) became President & CEO. Hiroshi Shimada became Representative Director. Yoshiji Ishida (Representative Director, Executive Vice President, planning, finance, IT, procurement) retired to become Special Advisor

Board said the new team should design and execute the next plan starting FY2026. Both new representative directors had pharma experience (Yakuji Nippo)

Jun 2025

Mitsuhiro Tsubakimoto joined as outside director; Yo Ota left the board (named in Yuho attendance records); Takeshi Saito replaced Megumi Machida as Standing Senior Auditor

Routine AGM rotation

Nov 2025

Inoue's portfolio narrowed: Procurement removed from his responsibilities

Organisational change

Jun 2021

Yukio Tachibana (Representative Director, Executive Vice President) retired; Tomoo Shibuya became Representative Director, Senior Managing Executive Officer

Jiho, May 2021

Major Shareholders

RankShareholderShares (k)%
1

The Master Trust Bank of Japan (trust a/c)

22,02914.83
2

Custody Bank of Japan (trust a/c)

11,0557.44
3

Kaya Best Club (business-partner shareholding association)

6,0924.10
4

The Joyo Bank

5,0893.43
5

Meiji Yasuda Life Insurance

4,8433.26
6

Northern Trust (AVFC) re Silchester International Investors International Value Equity Trust

4,1332.78
7

Chugai Sangyo

3,4402.32
8

MUFG Bank

3,4102.30
9

Northern Trust (AVFC) re US Tax-Exempted Pension Funds

2,7911.88
10

State Street Bank and Trust 505001

2,6411.78

Competitive Landscape

Competitors by Segment

Segment / productCompetitorsRelative positioning

Airbag inflators

Daicel (Safety SBU; Japan), Autoliv (in-house inflators; Sweden/US), ZF (Germany), Joyson Safety Systems (China/US), ARC Automotive (US)

NK is a merchant (non-module) inflator supplier with strong Chinese local-OEM exposure. Autoliv is the global safety-module leader (2025 sales ≈ USD 10.8 bn)

MGGs and squibs

Daicel, Autoliv, ZF, Joyson

NK claims the No. 1 global share in MGGs (company)

Polarisers / optical (niche)

Nitto Denko, Sumitomo Chemical (mass LCD polarisers); niche HUD optics makers

NK competes only in high-durability dye-based and niche optical segments

X-ray components

Hamamatsu Photonics, Amptek (Ametek), Ketek

Moxtek and Rayspec are niche specialists

Semiconductor epoxy resins

DIC (expanding Chiba epoxy plant by about 59%), Mitsubishi Chemical, Nippon Steel Chemical & Material, Resonac

NK cited as world No. 1 in encapsulant epoxy (Monex profile); a DIC capacity build is a share threat

MEMS / thick-film resists

DuPont, JSR, Tokyo Ohka Kogyo, Merck

SU-8 franchise via KAM

Inkjet and functional dyes

Fujifilm, Orient Chemical, Sumitomo Chemical, Huntsman (textile dyes)

NK described as Japan's largest dye maker (Monex profile)

Acrylic-acid catalysts

Mitsubishi Chemical and Nippon Shokubai (captive), BASF, Clariant

NK claims the No. 1 global merchant share (company)

Oncology generics and biosimilars (Japan)

Sawai Group, Towa Pharmaceutical, Nichi-Iko, Daiichi Sankyo Espha, Pfizer, Celltrion, Fuji Pharma

NK is a leading domestic oncology supplier (company)

Innovative oncology (Japan)

Chugai, Daiichi Sankyo, Takeda, AstraZeneca, Pfizer (ROS1: crizotinib; Chugai's entrectinib; BMS's repotrectinib)

Ibtrogy is the fourth ROS1 TKI in Japan

Agrochemicals

Kumiai Chemical, Nihon Nohyaku, Sumitomo Chemical, Nissan Chemical

Niche player

Peer Comparison FY2025

MetricNippon Kayaku (FY to Mar-2026)Daicel (FY to Mar-2026)DIC (FY to Dec-2025)Autoliv (FY to Dec-2025)

Revenue

JPY 241.9 bn

JPY 579.6 bn

JPY 1,052.2 bn

≈ USD 10.8 bn

Revenue growth YoY

+8.7%-1.2%-1.8%+4.1%

Operating margin

9.3%7.3%5.0%

≈ 10.0%

Net income attributable

JPY 24.6 bn

JPY 10.2 bn (JPY 32.8 bn COC-resin impairment)

JPY 32.4 bn

USD 9 EPS (company)

R&D / sales

5.2% (total R&D basis)

———

Current-year guidance

Sales JPY 270.9 bn; OI JPY 27.3 bn

Sales JPY 595 bn; OI JPY 42.5 bn

Sales JPY 1.1 tn; OI JPY 56 bn

Organic growth ≈0%; adj. margin 10.5–11.0%

Recent Developments

Special retirement payments of JPY 335 M (FY2024) and JPY 100 M (FY2025) were booked. Consolidated headcount fell slightly (−33) in FY2025.

In 2024, Japan's OEM type-certification irregularities depressed first-half FY2024 domestic Safety Systems volumes (company commentary, Nov 2024 briefing).

Company Snapshot

$1,615.6M

Revenue

5,946

Employees

1916

Founded

SWOT Analysis

Strengths

  • Record and diversified top line: fifth consecutive record sales of JPY 241.9 bn in FY2025, with three segments each contributing 30–39% (Yuho FY2025).
  • Global leadership niches: No. 1 claimed in MGGs and acrylic-acid catalysts; leading in squibs and semiconductor epoxy (investor presentation, July 2026).
  • Strong balance sheet: equity ratio 70.0%; net cash JPY 5.3 bn; interest coverage about 48x (FY2025).
  • FC profitability rebound: segment margin at a record 16.1% and segment ROA 12.3% in FY2025 on AI/high-end semiconductor demand.
  • Rebuilt oncology pipeline: Ibtrogy launched November 2025, with data showing confirmed response rates of 88.8% in treatment-naïve and 55.8% in pre-treated patients (pooled TRUST-I/II per CareNet); Zoladex acquisition; Portrazza label expansion.
  • Shareholder-return commitment: FY2025 total payout 106.2%; 16.8 M shares cancelled over the past 17 months (5.0 M in May 2025, 11.3 M in May 2026); no dividend cut in 46 years per the company.

Weaknesses

  • Margin erosion: gross margin down from 34.6% (FY2021) to 30.1% (FY2025); operating margin 9.3% versus 11.4% in FY2021.
  • Sub-par capital efficiency: ROE averaged about 6% over FY2021–FY2024; KV25 ROE and OI targets were missed (OI JPY 22.4 bn vs. JPY 26.5 bn plan).
  • Weak free cash flow: FY2024 FCF was −JPY 3.7 bn and FY2025 FCF JPY 4.3 bn (1.8% margin), as capex reached JPY 24–29 bn.
  • Working-capital intensity: cash conversion cycle about 237 days; inventories up JPY 12.8 bn in FY2025 to JPY 84.3 bn.
  • Earnings quality: JPY 9.4 bn of securities gains made up about 28% of FY2025 pre-tax income; the FY2026 forecast assumes lower one-offs (NI guidance initially −9.5%).
  • Project execution delays: Asa epoxy plant completion pushed two years to January 2028; Fukuyama dry-film plant to April 2028 (Yuho FY2025).

Opportunities

  • Chinese and Indian vehicle safety-content growth; Chinese local-OEM demand drove FY2025 Safety growth (Yuho).
  • AI servers and advanced packaging: low-dielectric and maleimide resins; next-generation power-semiconductor materials (Yuho R&D section).
  • Pharma CDMO and supply-gap capture: Toyama plant (about JPY 3 bn of sales) plus Takasaki biologics and injectables lines; management is considering further plant acquisitions (Yakuji Nippo, April 2026).
  • Inorganic growth capacity: debt/EBITDA about 1.3x leaves room for leveraged M&A toward the JPY 500 bn FY2035 ambition.
  • New mobility and energy adjacencies: PARASAFE with Rainmaker; eVTOL parachutes; NEDO-backed anion-exchange membranes.
  • Rerating potential: P/B at about 1.1x and P/E at about 13.8x forecast (Kabuyoho, 25 September 2026), with a consensus target of JPY 2,800 implying about 31% upside.

Threats

  • Raw-material inflation: M&I profit fell 20% in FY2025 despite +3.7% sales.
  • NHI drug-price revisions and biosimilar pricing pressure; management flagged the biosimilar market as difficult (November 2025).
  • Geopolitics and tariffs: US tariffs affected Safety Systems in FY2025; US sales fell 15.6%; dependence on China (21% of sales) adds risk.
  • FX: 56% overseas sales. Q1 FY2026 benefited from a weak yen; appreciation would reverse that.
  • Operational hazards: an explosives and chemicals footprint (Asa fire, November 2025); disaster risk ranked among principal risks.
  • Competitive capacity: DIC's subsidised epoxy expansion (+59% capacity); Chinese inflator competitors.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
28 Mar 2025 (context)CEO succession announced; cost-of-capital plan; JPY 17 bn buyback authorisedSets the governance and capital agenda
10 Apr 2025Nov-2024 buyback programme closed (about 4.0 M shares, about JPY 5.25 bn cumulative)Capital return
13 May 2025FY2024 results: sales +10.3%, net income +325.6%; DPS raised to JPY 60Recovery from FY2023 trough
23 May 20255,003,570 treasury shares cancelled (issued shares to 160.0 M)Share count reduction
30 May 2025Adlai Nortye: buparlisib Phase 3 BURAN misses OS endpoint; development discontinuedLoss of an expected Japanese pipeline asset
26 Jun 2025AGM: Kawamura appointed President & CEO; Shimada Representative Director; Tsubakimoto joins as outside directorLeadership transition
Aug 2025Q1 FY2025: sales JPY 54.8 bn, OI JPY 4.4 bnSlow start on cost pressures
19 Sep 2025Ibtrogy (taletrectinib) approved in JapanFirst major in-licensed new drug under KV25
11 Nov 20251H FY2025: sales JPY 113.6 bn (+4.1%), OI JPY 10.6 bn (−4.9%), NI JPY 11.7 bn (+95.7%, securities gains); interim DPS JPY 30Underlying margin pressure masked by asset sales
12 Nov 2025Ibtrogy launched; Evolution2035 policy presentedPharma growth; strategy reset
12 Nov 2025Pharma management calls the biosimilar market difficult, citing total-value transactions and trial-waiver regulationSignals pricing headwinds
28 Nov 2025Fire at the Asa Plant (Kawahigashi); JPY 334 M lossOperational risk event
Dec 2025Kayaku (Shanghai) Management liquidatedSimplification
13 Jan 2026Eisai licenses taletrectinib ex-US/CN/JP rights (EUR 50 M upfront to Nuvation)External validation of Ibtrogy
2 Feb 2026Q3 FY2025: 9M sales JPY 174.6 bn, OI JPY 16.3 bnOn track
18 Feb 2026Pharma head targets new drugs at about 30% of pharma sales in about 10 years; biologics line at TakasakiPharma structural shift
26 Mar 2026Mar-2025 buyback completed: 11,224,800 shares for JPY 16.2 bnCapital return
30 Mar 2026Agreement to acquire Fuji Yakuhin's Toyama No. 2 injectables plantCDMO entry
1 Apr 2026Evolution2035 begins; Mirai Biz CenterStrategy
12 May 2026FY2025 results (record sales JPY 241.9 bn; NI +40.7%; ROE 9.0%); Phase 1 targets (FY2028: JPY 300 bn sales, JPY 36 bn OI, ROE ≥10%); new JPY 15 bn / 13 M-share buyback; cancellation of 11.3 M shares; FY2026 guidanceCapital-efficiency push
21–25 May 2026Zoladex MAH transfer agreed with AstraZenecaPortfolio addition
22 May 202611.3 M shares (7.06%) cancelled; issued shares to 148.7 MShare count reduction
19 Jun 2026FY2025 Yuho filed; President's pay JPY 111 MDisclosure
25 Jun 2026AGM; year-end DPS JPY 36 (annual JPY 66)Shareholder return
17 Jul 2026Investor presentation: FY2035 ambition of JPY 500 bn sales and ROE ≥15%Long-term targets
3 Aug 2026Q1 FY2026: record sales JPY 67.4 bn (+23.1%); ordinary income JPY 7.39 bn (+81.7%); NI JPY 6.08 bn (+41.7%); guidance raised to JPY 270.9 bn sales / JPY 27.3 bn OI. Pharma Q1 sales reportedly +27.8% (Jiho)Strong start; upward revision
7–8 Sep 2026Sanko Chemical Industry squeeze-out notice (89.7% held)Group simplification
28 Sep 2026Parent-company earnings / tax item
1 Oct 2026Toyama plant acquisition completedCDMO capacity online
6 Oct 2026Buyback execution

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Net sales rose from JPY 184.8 Bn in FY2021 to JPY 241.9 Bn in FY2025.
Nippon Kayaku Co., Ltd. — Income Statement: Revenue & Gross Profit
Series (JPY Bn)FY2021FY2022FY2023FY2024FY2025
Net sales184.8198.4201.8222.6241.9
Gross profit6466.861.371.572.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.